Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes.

Diabetes technology & therapeutics - 1 Sept 2016

Ren Qian, Xiao Di, Han Xueyao, Edwards Stacey L, Wang Huaiqing, Tang Yong, Zhang Simin, Li Xi, Zhang Xiuying, Cai Xiaoling, Liu Zhaoqian, Paul Sanjoy K, Ji Linong

Abstract excerpt

BACKGROUND: Sulfonylureas are widely used to treat type 2 diabetes (T2DM). Although genetic variations are associated with sulfonylurea treatment responses in T2DM patients, whether these variations can be used to predict heterogeneous treatment responses is unclear. In this study, we assessed the potential utility of combining information from multiple variants and phenotypes to predict sulfonylurea response....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Double-Blind Method
Share to Glucuronosyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glyburide

Share to Hypoglycemic Agents

Share to Oxygenases

Share to Sterol 14-Demethylase

Share to Sulfonylurea Compounds

Share to Treatment Failure

Source

Identifiers

PMID: 27403931
DOI: 10.1089/dia.2015.0427

Genes

FMO2
FMO3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes.PMID 27403931Read ↗

Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China.Semantic proximity Read ↗

Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphismsSemantic proximity Read ↗

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicineSemantic proximity Read ↗

Combined Influence of Genetic Variants and Gene-gene Interaction on Sulfonylurea Efficacy in Type 2 Diabetic Patients.Semantic proximity Read ↗

Pharmacogenetic studies update in type 2 diabetes mellitusSemantic proximity Read ↗

Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to SulfonylureasSemantic proximity Read ↗

Pharmacogenetics and personalized treatment of type 2 diabetesSemantic proximity Read ↗

Personalized medicine in diabetes: the role of ‘omics’ and biomarkersSemantic proximity Read ↗

Influence of the SLCO1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China.Semantic proximity Read ↗

Pharmacogenomics of Oral Antidiabetic Medications: Current Data and Pharmacoepigenomic PerspectiveSemantic proximity Read ↗

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Semantic proximity Read ↗

Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.